Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease

Inclusion Criteria: * Men and women ages from 18 to 85 years old. * Group 1: For moderate dry macular degeneration the BCVA must be between 50 and 70 (ETDRS) at Screening Visit V1. There must be a large drusen \>125 µm within 1mm from the centre of the fovea. Geographic atrophy can be present but must be \>300 µm away from centre of fovea; * Group 2: For severe dry macular degeneration the BCVA must be between 41 and 49 (ETDRS) at Screening Visit V1. Geographic atrophy can involve the fovea but must be \<2500 µm in diameter or any size GA but \>200 µm from centre of fovea anywhere; * Group 3: For moderate Stargardt disease the BCVA must be between 50 and 70 (ETDRS) at Screening Visit V1. The geographic area must be \<2.0 mm in diameter anywhere; * Group 4: For severe Stargardt disease the BCVA must be between 41 and 49 (ETDRS) at Screening Visit V1. The geographic area must be \<2.5 mm in diameter anywhere; * Willingness to take the randomised trial investigational product for 6 months; * Willingness to consent and undergo the examinations/blood testing at the visits; * Be able to swallow large soft gel capsules; * Take other supplements as usual; The EPA and DHA intake must be less than 1200 mg/day. Exclusion Criteria: * Any ocular disease in either eye including: Diabetic retinopathy, Central serous retinopathy, Epiretinal membrane, Optic atrophy, Macular hole or pseudohole, Retinal vein occlusion, Amblyopia; * Previous wet AMD in the study eye; * Any previous ocular sur…